Global Huntington's Disease Therapeutics Market 2014-2018

ハンチントン病治療薬の世界市場

◆タイトル:Global Huntington's Disease Therapeutics Market 2014-2018
◆商品コード:IRTNTR4355
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年10月22日
◆ページ数:72
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥316,400見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、"ハンチントン病治療薬の世界市場"について調査・分析し、エグゼクティブサマリー、市場概観、市場規模及び予測、主要地域別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析等の情報をお届けいたします。

About Huntington’s Disease
Huntington’s disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. People with Huntington’s disease often develop chorea that causes involuntary muscle movements of hands, face, trunk, and feet.

The behavioural disorders associated with the disease include depression, psychosis, and changes in personality. Other symptoms of the disease include speech impairment, anxiety, stress, and difficulty in swallowing. People suffering from Huntington’s disease usually develop symptoms in their mid-30s and 40s. However, in few cases, disease symptoms appear in childhood or teens. The former case represents the adult-onset form of the disease, while the latter is the early-onset form. The early-onset form is associated with symptoms such as tremors, slow movements, and rigidity. Children with early-onset disease rarely live to adulthood. Currently, there is no approved treatment for Huntington’s disease.

TechNavio’s analysts forecast the Global Huntington’s Disease Therapeutics market to grow at a CAGR of 29.46 percent over the period 2013-2018.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Global Huntington’s Disease Therapeutics market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of drugs approved for the treatment of symptoms of Huntington’s disease.

TechNavio’s report, the Global Huntington’s Disease Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Huntington’s Disease Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Lundbeck
• Valeant Pharmaceuticals International

[Other Prominent Vendors]
• Auspex Pharmaceuticals
• GlaxoSmithKline
• Ipsen
• Omeros
• Palobiofarma
• Pfizer
• Prana Biotechnology
• Raptor Pharmaceutical
• Siena Biotech
• SOM Biotech
• Teva Pharmaceutical Industries

[Market Driver]
• Unmet Medical Needs
• For a full, detailed list, view our report

[Market Challenge]
• Poor Diagnosis Rates
• For a full, detailed list, view our report

[Market Trend]
• Novel Mechanisms Targeted by Pipeline Candidates
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Prevalence of Huntington’s Disease
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Drug Class
09. Geographical Segmentation
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.2 Market Share Analysis 2013
17.3 Potential Future Vendors
18. Clinical-stage Pipeline Candidates
19. Key Information of Clinical-stage Pipeline Candidates
19.1 SD-809ER
19.2 RP103
19.3 ABR-215062
19.4 BN82451
19.5 OMS824
19.6 PF-02545920
19.7 SEN0014196
19.8 TV-7820
19.9 PBT2
19.10 GSK356278
19.11 PBF-999
20. Discontinued Clinical-stage Pipeline Drugs
21. Key Vendor Analysis
21.1 H. Lundbeck
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Product Segmentation by Revenue 2013
21.1.4 Product Segmentation by Revenue 2012 and 2013
21.1.5 Geographical Segmentation by Revenue 2013
21.1.6 Business Strategy
21.1.7 Recent Developments
21.1.8 SWOT Analysis
21.2 Valeant Pharmaceuticals International
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation by Revenue 2013
21.2.4 Business Segmentation by Revenue 2012 and 2013
21.2.5 Sales by Geography
21.2.6 Business Strategy
21.2.7 Key Developments
21.2.8 SWOT Analysis
22. Other Reports in this Series

[List of Exhibits]
Exhibit 1: Market Research Methodology
Exhibit 2: Prevalence of Huntington’s Disease by Geography 2013
Exhibit 3: Global Huntington’s Disease Therapeutics Market 2013-2018 (US$ million)
Exhibit 4: Global Huntington’s Disease Therapeutics Market by Drug Class
Exhibit 5: Global Huntington’s Disease Therapeutics Market by Geographical Segmentation 2013
Exhibit 6: Global Huntington’s Disease Therapeutics Market Share Analysis 2013
Exhibit 7: Key Regulatory Approvals of Tetrabenazine
Exhibit 8: Key Events of Xenazine
Exhibit 9: Valeant Pharmaceuticals International Inc.: Sales of Xenazine 2008-2013 (US$ million)
Exhibit 10: Valeant Pharmaceuticals International Inc.: Sales of Xenazine by Geography 2013
Exhibit 11: H. Lundbeck A/S: Sales of Xenazine 2009-2013 (US$ million)
Exhibit 12: H. Lundbeck A/S: Quaterly Sales of Xenazine 2009-2013 (US$ million)
Exhibit 13: H. Lundbeck: Business Segmentation by Revenue 2013
Exhibit 14: H. Lundbeck: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 15: H. Lundbeck: Geographical Segmentation by Revenue 2013
Exhibit 16: Valeant Pharmaceuticals International Inc.: Business Segmentation by Revenue 2013
Exhibit 17: Valeant Pharmaceuticals International Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 18: Valeant Pharmaceuticals International Inc.: Sales by Geography 2013



【掲載企業】

Lundbeck ,Valeant Pharmaceuticals International ,Auspex Pharmaceuticals,GlaxoSmithKline,Ipsen,Omeros ,Palobiofarma,Pfizer,Prana Biotechnology,Raptor Pharmaceutical,Siena Biotech,SOM Biotech,Teva Pharmaceutical Industries

【資料のキーワード】

ハンチントン病、治療薬、治験、製薬、パイプライン

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[ハンチントン病治療薬の世界市場] (Global Huntington's Disease Therapeutics Market 2014-2018 / IRTNTR4355)販売に関する免責事項
[ハンチントン病治療薬の世界市場] (Global Huntington's Disease Therapeutics Market 2014-2018 / IRTNTR4355)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆